NASDAQ:CRDF Cardiff Oncology (CRDF) Stock Price, News & Analysis $2.90 -0.04 (-1.36%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cardiff Oncology Stock (NASDAQ:CRDF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cardiff Oncology alerts:Sign Up Key Stats Today's Range$2.81▼$2.9950-Day Range$2.38▼$4.7752-Week Range$2.01▼$5.64Volume1.02 million shsAverage Volume1.13 million shsMarket Capitalization$192.92 millionP/E RatioN/ADividend YieldN/APrice Target$11.67Consensus RatingBuy Company OverviewCardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Read More… Cardiff Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreCRDF MarketRank™: Cardiff Oncology scored higher than 17% of companies evaluated by MarketBeat, and ranked 835th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCardiff Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCardiff Oncology has only been the subject of 1 research reports in the past 90 days.Read more about Cardiff Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cardiff Oncology are expected to grow in the coming year, from ($0.99) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiff Oncology is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiff Oncology is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiff Oncology has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cardiff Oncology's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted31.41% of the float of Cardiff Oncology has been sold short.Short Interest Ratio / Days to CoverCardiff Oncology has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in Cardiff Oncology has recently increased by 11.02%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCardiff Oncology does not currently pay a dividend.Dividend GrowthCardiff Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted31.41% of the float of Cardiff Oncology has been sold short.Short Interest Ratio / Days to CoverCardiff Oncology has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in Cardiff Oncology has recently increased by 11.02%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Cardiff Oncology this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for CRDF on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cardiff Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cardiff Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.80% of the stock of Cardiff Oncology is held by insiders.Percentage Held by InstitutionsOnly 16.29% of the stock of Cardiff Oncology is held by institutions.Read more about Cardiff Oncology's insider trading history. Receive CRDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDF Stock News HeadlinesCardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve PatientsApril 23 at 4:15 PM | globenewswire.comCardiff Oncology completes patient enrollment in CRDF-004 trialApril 16, 2025 | markets.businessinsider.comTop Picks for Trump’s Pro-Crypto AmericaJust Announced: What Trump’s Move Means for Crypto—Join Now 27 top names reveal urgent insights as Bitcoin reboundsApril 24, 2025 | Crypto 101 Media (Ad)Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 15, 2025 | globenewswire.comCardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal CancerApril 15, 2025 | globenewswire.comCardiff Oncology (CRDF) Receives a Buy from Piper SandlerApril 14, 2025 | markets.businessinsider.comCardiff Oncology initiated with a Buy at Lucid CapitalApril 4, 2025 | markets.businessinsider.comEarnings call transcript: Cardiff Oncology Q4 2024 highlights strategic advancesMarch 1, 2025 | uk.investing.comSee More Headlines CRDF Stock Analysis - Frequently Asked Questions How have CRDF shares performed this year? Cardiff Oncology's stock was trading at $4.34 at the beginning of the year. Since then, CRDF shares have decreased by 33.2% and is now trading at $2.90. View the best growth stocks for 2025 here. How were Cardiff Oncology's earnings last quarter? Cardiff Oncology, Inc. (NASDAQ:CRDF) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.02. The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.13 million. Cardiff Oncology had a negative trailing twelve-month return on equity of 73.97% and a negative net margin of 6,238.17%. Who are Cardiff Oncology's major shareholders? Cardiff Oncology's top institutional shareholders include Yarbrough Capital LLC (0.13%), Rhumbline Advisers (0.09%), Brighton Jones LLC (0.02%) and Castleview Partners LLC (0.02%). Insiders that own company stock include Gary W Pace, Lale White, James E Levine and Mark Erlander. View institutional ownership trends. How do I buy shares of Cardiff Oncology? Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cardiff Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Digital Turbine (APPS), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/07/2024Today4/24/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRDF CIK1213037 Webcardiffoncology.com Phone(858) 952-7570FaxN/AEmployees20Year Founded1999Price Target and Rating Average Stock Price Target$11.67 High Stock Price Target$17.00 Low Stock Price Target$8.00 Potential Upside/Downside+310.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,440,000.00 Net Margins-6,238.17% Pretax Margin-6,238.17% Return on Equity-73.97% Return on Assets-60.40% Debt Debt-to-Equity RatioN/A Current Ratio4.74 Quick Ratio4.74 Sales & Book Value Annual Sales$683,000.00 Price / Sales277.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.56 per share Price / Book1.82Miscellaneous Outstanding Shares66,524,000Free Float47,146,000Market Cap$189.26 million OptionableOptionable Beta1.74 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:CRDF) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Collapse Is Already HereWhen a system is about to fail, those trained to spot it often notice before anyone else. Tim Plaehn flew high...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.